Richard Shelton
Psychiatry · Birmingham, ALNPI 1285726612
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $73,158 of the $79,293 with a category attached, or 92.3%. 12 manufacturers reported payments, led by Janssen Scientific Affairs, LLC at 33.2% of the total. Reporting peaked in 2023 at $20,051 and has fallen 81.2% since, to $3,761 in 2025. Among psychiatry clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 77 payments — averaging $1029.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Scientific Affairs, LLC$26K
- Janssen Research & Development, LLC$21K
- AbbVie$10K
- Alfasigma USA, Inc.$8K
- Johnson & Johnson$7K
- Boehringer Ingelheim International GmbH$4K
- plus $3K from 6 others
Across 487 payments — averaging $4857.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$1.5M
- Sumitomo Pharma America, Inc.$187K
- Supernus Pharmaceuticals, Inc.$138K
- AbbVie$127K
- Novartis$106K
- Livanova USA, Inc.$103K
- plus $164K from 4 others
What the payments were for
- Consulting fees$73,15892%
- Travel & lodging$5,2377%
- Food & beverage$8981%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Scientific Affairs, LLC | 20 | $26,300 |
| Janssen Research & Development, LLC | 23 | $21,356 |
| AbbVie | 11 | $9,967 |
| Alfasigma USA, Inc. | 3 | $7,565 |
| Johnson & Johnson | 8 | $6,713 |
| Boehringer Ingelheim International GmbH | 3 | $4,200 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $3,000 |
| Axsome Therapeutics, Inc. | 2 | $80 |
| Supernus Pharmaceuticals, Inc. | 1 | $35 |
| Neurocrine Biosciences, Inc. | 1 | $31 |
| GSK | 1 | $23 |
| Livanova USA, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$79,293 in reported general payments places this provider in the 95th percentile of 400 psychiatry providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other psychiatry in Birmingham
- Armand SchachterBirmingham$758K
- Stephen HughesBirmingham$683K
- Leesha Ellis CoxBirmingham$653K
- Godehard OepenBirmingham$516K
- Melissa KarrhBirmingham$51K
- Matthew MacalusoBirmingham$49K
- Santosh PillaiBirmingham$28K
- Jennifer HadleyBirmingham$27K
- Kerry ClearyBirmingham$12K
- Praveen JettyBirmingham$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.